Clinton Bybee
CIK 1219043 · last filed 2022-08-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1025
CHICAGO, IL 60631
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VIR | 10%+ Owner | 208,852 | $11.04 | $2.31M | $0 | 2 | 2022-08-16 |
| BEAM | 10%+ Owner | 2,949,630 | $23.79 | $70.17M | $0 | 1 | 2021-07-02 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | 10%+ Owner | 1,532,049 | $329.83 | $505.32M | $22.40M | 3 | 2021-01-12 |
| PI | Director | 17,125 | $172.23 | $2.95M | $97.7K | 14 | 2020-10-23 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 158,734 | $0.49 | $78.6K | $20.93M | 1 | 2020-09-22 |
| DNLI | 10%+ Owner | 10,668,749 | $18.66 | $199.08M | $0 | 1 | 2019-08-12 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 430,205 | $0.00 | $172 | -$2.94M | 1 | 2019-07-17 |
| Unity Biotechnology, Inc. (UBX) Delisted | 10%+ Owner | 629,860 | $0.20 | $126.0K | $0 | 1 | 2018-05-07 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | 10%+ Owner | 2,750,575 | — | — | $0 | 1 | 2017-08-01 |
| XCOM | Director | 1,885,090 | $29.00 | $54.66M | $7.50M | 5 | 2016-10-13 |
| VBI VACCINES INC. (VBIV) Delisted | 10%+ Owner | 134,928 | $0.07 | $8.8K | $0 | 1 | 2015-08-17 |
| PULM | 10%+ Owner | — | $1.44 | — | $0 | 1 | 2015-06-25 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 2,124,699 | $8.68 | $18.44M | $0 | 2 | 2015-06-22 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | 10%+ Owner | 64,377 | $0.01 | $773 | $12.76M | 1 | 2015-02-23 |
| AGIO | 10%+ Owner | 3,088,590 | $36.85 | $113.81M | $0 | 2 | 2015-02-23 |
| Juno Therapeutics, Inc. (JUNO) Delisted | 10%+ Owner | 7,347,015 | — | — | $0 | 1 | 2014-12-23 |
Recent Filings · Page 3 of 4
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-08-01 | Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | Conv (C) | +21,798,408 | $0 | EDGAR |
| 2017-06-16 | PI | Grant (A) | — | $0 | EDGAR |
| 2017-02-23 | PI | Other (J) | +417 | $0 | EDGAR |
| 2016-10-13 | XCOM | Buy (P) | — | $0 | EDGAR |
| 2016-09-28 | XCOM | Buy (P) | — | $0 | EDGAR |
| 2016-09-15 | XCOM | Buy (P) | — | $0 | EDGAR |
| 2016-08-30 | PI | Mixed | +1,366,735 | $204 | EDGAR |
| 2016-07-26 | PI | Mixed | +1,361,408 | $68 | EDGAR |
| 2016-05-25 | — | Mixed | +2,239,587 | $34.95M | |
| 2015-11-18 | XCOM | Mixed | +1,864,745 | $1.50M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.